All In Biotech

Drug Trial Radar · NCT05278975

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Mar 31, 2022

Primary completion

Nov 30, 2025

Study completion May 7, 2026

Sponsor

Lead sponsor
RS Oncology LLCIndustry
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.

Conditions

  • Malignant Pleural Effusion
  • Malignant Pleural Mesothelioma
  • Mesothelioma
  • Mesotheliomas Pleural
  • Mesothelioma; Lung
  • Pleural Effusion, Malignant

Interventions

  • RSO-021Drug

    A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting ToxicityTime frame: First 21 days of treatment.
  2. Frequency and Severity of Adverse Events (AE)Time frame: Screening to 90 days from last dose.
  3. Dose FindingTime frame: Screening to 90 days from last dose.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Greater Glasgow & Clyde

    Glasgow, United Kingdom

  • Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary

    Leicester, United Kingdom

  • Barts Health NHS Cancer Institute

    London, United Kingdom

  • Guys and St Thomas NHS Foundation Trust

    London, United Kingdom

  • The Royal Marsden

    London, United Kingdom

  • The Christie NHS

    Manchester, United Kingdom

  • Oxford University Hospitals NHS Foundation

    Oxford, United Kingdom

  • South Mead North Bristol Hopsital

    Bristol, Bristol, United Kingdom

  • Leeds Teaching Hospital

    Leeds, Leeds, United Kingdom

  • Northumbria NorthTyne Side General Hospital

    North Shields, North Shields, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.